Switch theme
Sign up to access all valuation multiples
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
2010
n/a
Last FY Revenue $48.5M
Last FY EBITDA $9.8M
$334M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Jiangsu Bioperfectus achieved revenue of $48.5M and an EBITDA of $9.8M.
Jiangsu Bioperfectus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Bioperfectus valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $48.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $30.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 62% | XXX | XXX | XXX |
| EBITDA | XXX | $9.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 20% | XXX | XXX | XXX |
| EBIT | XXX | -$5.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -11% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.3M | XXX | XXX | XXX |
| Net Margin | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jiangsu Bioperfectus's stock price is CNY 70 (or $10).
Jiangsu Bioperfectus has current market cap of CNY 4.0B (or $553M), and EV of CNY 2.4B (or $334M).
See Jiangsu Bioperfectus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $334M | $553M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jiangsu Bioperfectus has market cap of $553M and EV of $334M.
Jiangsu Bioperfectus's trades at 6.9x EV/Revenue multiple, and 34.1x EV/EBITDA.
Equity research analysts estimate Jiangsu Bioperfectus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Bioperfectus's P/E ratio is not available.
See valuation multiples for Jiangsu Bioperfectus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $553M | XXX | $553M | XXX | XXX | XXX |
| EV (current) | $334M | XXX | $334M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 34.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -62.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1991.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 29.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiangsu Bioperfectus's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Jiangsu Bioperfectus's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangsu Bioperfectus's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiangsu Bioperfectus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Bioperfectus acquired XXX companies to date.
Last acquisition by Jiangsu Bioperfectus was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Bioperfectus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jiangsu Bioperfectus founded? | Jiangsu Bioperfectus was founded in 2010. |
| Where is Jiangsu Bioperfectus headquartered? | Jiangsu Bioperfectus is headquartered in China. |
| Is Jiangsu Bioperfectus publicy listed? | Yes, Jiangsu Bioperfectus is a public company listed on SHG. |
| What is the stock symbol of Jiangsu Bioperfectus? | Jiangsu Bioperfectus trades under 688399 ticker. |
| When did Jiangsu Bioperfectus go public? | Jiangsu Bioperfectus went public in 2019. |
| Who are competitors of Jiangsu Bioperfectus? | Similar companies to Jiangsu Bioperfectus include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Jiangsu Bioperfectus? | Jiangsu Bioperfectus's current market cap is $553M |
| Is Jiangsu Bioperfectus profitable? | Yes, Jiangsu Bioperfectus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
